| Autor: |
Antonova LV; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia. antonova.la@mail.ru., Silnikov VN; Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia. silnik@niboch.nsc.ru., Sevostyanova VV; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia. sevostv@gmail.com., Yuzhalin AE; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia. yuzhalin@gmail.com., Koroleva LS; Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia. koroleva@niboch.nsc.ru., Velikanova EA; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia. veliea@cardio.kem.ru., Mironov AV; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia. a.mir.80@mail.ru., Godovikova TS; Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia. godov@niboch.nsc.ru., Kutikhin AG; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia. antonkutikhin@gmail.com., Glushkova TV; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia. bio.tvg@mail.ru., Serpokrylova IY; Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia. inna_serpokrylova@biosset.com., Senokosova EA; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia. sergeewa.ew@yandex.ru., Matveeva VG; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia. matveeva_vg@mail.ru., Khanova MY; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia. Khanovam@gmail.com., Akentyeva TN; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia. t.akentyeva@mail.ru., Krivkina EO; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia. leonora92@mail.ru., Kudryavtseva YA; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia. jackie1970@mail.ru., Barbarash LS; Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia. reception@kemcardio.ru. |
| Abstrakt: |
Modification with Arg-Gly-Asp (RGD) peptides is a promising approach to improve biocompatibility of small-calibre vascular grafts but it is unknown how different RGD sequence composition impacts graft performance. Here we manufactured 1.5 mm poly(3-hydroxybutyrate- co -3-hydroxyvalerate)/poly(ε-caprolactone) grafts modified by distinct linear or cyclic RGD peptides immobilized by short or long amine linker arms. Modified vascular prostheses were tested in vitro to assess their mechanical properties, hemocompatibility, thrombogenicity and endothelialisation. We also implanted these grafts into rat abdominal aortas with the following histological examination at 1 and 3 months to evaluate their primary patency, cellular composition and detect possible calcification. Our results demonstrated that all modes of RGD modification reduce ultimate tensile strength of the grafts. Modification of prostheses does not cause haemolysis upon the contact with modified grafts, yet all the RGD-treated grafts display a tendency to promote platelet aggregation in comparison with unmodified counterparts. In vivo findings identify that cyclic Arg-Gly-Asp-Phe-Lys peptide in combination with trioxa-1,13-tridecanediamine linker group substantially improve graft biocompatibility. To conclude, here we for the first time compared synthetic small-diameter vascular prostheses with different modes of RGD modification. We suggest our graft modification regimen as enhancing graft performance and thus recommend it for future use in tissue engineering. |
